RT Journal Article
SR Electronic
T1 Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
JF Science
JO Science
FD American Association for the Advancement of Science
SP 643
OP 650
DO 10.1126/science.abc5902
VO 369
IS 6504
A1 Brouwer, Philip J. M.
A1 Caniels, Tom G.
A1 van der Straten, Karlijn
A1 Snitselaar, Jonne L.
A1 Aldon, Yoann
A1 Bangaru, Sandhya
A1 Torres, Jonathan L.
A1 Okba, Nisreen M. A.
A1 Claireaux, Mathieu
A1 Kerster, Gius
A1 Bentlage, Arthur E. H.
A1 van Haaren, Marlies M.
A1 Guerra, Denise
A1 Burger, Judith A.
A1 Schermer, Edith E.
A1 Verheul, Kirsten D.
A1 van der Velde, Niels
A1 van der Kooi, Alex
A1 van Schooten, Jelle
A1 van Breemen, Mariëlle J.
A1 Bijl, Tom P. L.
A1 Sliepen, Kwinten
A1 Aartse, Aafke
A1 Derking, Ronald
A1 Bontjer, Ilja
A1 Kootstra, Neeltje A.
A1 Wiersinga, W. Joost
A1 Vidarsson, Gestur
A1 Haagmans, Bart L.
A1 Ward, Andrew B.
A1 de Bree, Godelieve J.
A1 Sanders, Rogier W.
A1 van Gils, Marit J.
YR 2020
UL http://science.sciencemag.org/content/369/6504/643.abstract
AB Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They show that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell. A subset of antibodies was able to neutralize the virus. Competition and electron microscopy studies showed that these antibodies target diverse epitopes on the spike, with the two most potent targeting the domain that binds the host receptor.Science, this issue p. 643The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.